Introduction
Glutamate is the predominant excitatory neurotransmitter in the mammalian central nervous system. Glutamate transmission is mediated via interaction with the ligand-gated ion channel receptors, termed the ionotropic receptors, and the seven transmembrane domain G-protein coupled receptors, termed metabotropic glutamate receptors (Barnard, 1997; Schoepp et al., 1999) . Activation of these receptors is responsible for the physiological actions of glutamate, while paradoxically over-stimulation of the ionotropic receptors contributes to the excitotoxic actions attributed to glutamate. Consequently, synaptic glutamate levels must be tightly regulated in order to maintain the integrity of synaptic transmission and to limit or prevent the pathophysiological activity of this excitatory neurotransmitter.
A family of high-affinity Na + -dependent glutamate transporters expressed in the plasma membranes of both neurones and astroglia is responsible for the clearance of extracellular glutamate by mediating the cellular uptake of glutamate in a process driven largely by the energy of the transmembrane Na + gradient (see review by Danbolt, 1999) . Five members of this transporter family have been identified by molecular cloning and are designated EAAT1/GLAST, EAAT2/GLT-1, EAAT3/EAAC1, EAAT4 and EAAT5 (Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Arriza et al., 1994 Arriza et al., , 1997 Fairman et al., 1995) . Among the transporter subtypes EAAT2 accounts for the bulk of transport activity measured in forebrain preparations. The pharmacological profile of glutamate transport measured in rat forebrain preparations is well correlated with the pharmacology of the cloned rat GLT-1 and human EAAT2 subtypes expressed in mammalian cell lines (Dunlop et al., 1999; Tan et al., 1999) . Moreover, transgenic mice with a targeted This article has not been copyedited and formatted. The final version may differ from this version. deletion of the EAAT2 transporter lose greater than 90% of the forebrain glutamate transport capacity and exhibit increased vulnerability to an experimental head trauma insult (Tanaka et al., 1997) . Experiments using antisense oligonucleotides to knock down levels of EAAT2 resulted in reduced glutamate transport capacity, elevated extracellular glutamate and increased neurodegeneration (Rothstein et al., 1996) providing another line of evidence in support of a major role of EAAT2 in glutamate clearance.
A pharmacological elucidation of the functional role of EAAT2 has been hampered by the lack of potent and selective transport inhibitors. Widely utilized pharmacological tools such as the pyrollidine dicarboxylates (Bridges et al., 1991) , aminocyclobutane dicarboxylates (Fletcher et al., 1991) and carboxycyclopropyl glycines (Nakamura et al., 1993) suffer from combinations of poor selectivity across EAAT subtypes, rather modest potencies in the micromolar range and cross reactivity with glutamate receptor targets.
More recently, the threo-β-hydroxyaspartate derivative TBOA (threo-β-benzyloxyaspartate) and the novel heptane dicarboxylate WAY-855 (3-aminotricyclo[2.2.1.0 2.6 ]heptane-1,3-dicarboxylic acid) have been reported as novel EAAT inhibitors (Lebrun et al., 1997; Shimamoto et al., 1998; Dunlop et al., 2003) , and these agents provide some improvement over the earlier compounds. Subsequent structure activity relationship studies with TBOA have lead to the identification of nanomolar potent EAAT2 inhibitors with the most selective agent CNB-TBOA ((2S,3S)-3-[3-(4-methoxybenzoylamino)benzyloxy]aspartate)) exhibiting 39-fold selectivity over EAAT3 (Shimamoto et al., 1998) . Such agents are likely to be better tools for the characterization of transporter function.
This article has not been copyedited and formatted. The final version may differ from this version. Ci/mmol; 1 mCi/ml) in a final volume of 100 µl. Cells were washed with D-PBS before incubation with substrate in the absence or presence of compounds for 20 min at room temperature. Assays were stopped by aspiration followed by two ice-cold D-PBS washes.
Cells were solubilized with 0.5 N NaOH before addition of Microscint 20 for the determination of [ 3 H] accumulation in the wells using a Packard TopCount. Uptake was linear for incubation times up to 30 min (data not shown), thus data were analyzed as true rates. Non-specific uptake was corrected for by performing all experiments in the absence and presence of sodium (replacement of sodium chloride with choline chloride). Sodium independent uptake accounted for ≤ 10% of total uptake and was subtracted prior to any further data calculation.
Uptake in Rat Cortical Synaptosomes. P2 synaptosomal fractions isolated from rat cerebral cortex were prepared by homogenization of tissue in ice cold isolation medium (310 mM sucrose, 10 mM HEPES, pH 7.4) followed by centrifugation at 1000 g for 5 min. The resulting supernatant was collected and centrifuged at 20,000 g for 20 min to obtain the crude synaptosomal P2 pellet which was used for uptake studies at a protein This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. heteroexchange, while non-transportable inhibitors will either have no effect if efflux is limited or will block efflux. Synaptosomes were incubated with drug for 5 min at room temperature followed by centrifugation to separate pellet and supernatant. An aliquot of supernatant was subsequently removed for the determination of Data Analysis. IC 50 values for the dose response curves were generated using a 4
parameter logistic curve fitting model using OriginLabs Origin 7.5 (OriginLabs, Northampton , MA) using the following equation y=((A1-A2)/1+(x/x0)^p)+A2 where A1
is the maximum, A2 is the minimum, x0 is the IC 50 and p is the Hill slope coefficient.
This article has not been copyedited and formatted. The final version may differ from this version. In contrast, 100 µM WAY-213613 failed to activate any of the mGlu receptors examined (Figure 7 ). In addition, agonist-stimulated responses were blocked by the mGlu receptor antagonist LY341495, used at concentrations appropriate to each mGlu receptor studied, while 100 µM WAY-213613 failed to exhibit antagonist activity at any of the subtypes. hydrogen bond acceptor sites, positive ionizable (protonatable nitrogen), negative ionizable (acidic function) and two hydrophobic centers, was developed using both literature reported EAAT inhibitors and the novel compounds presented in this study (Fig. 9 ). and EAAT3 of 22-and 12-fold, respectively. Finally, the biaryl substituted diaminopropionic acid analog WAY-211686 also exhibited potent EAAT2 inhibitory activity but suffered from the poorest selectivity of the compounds examined; 9-and 8-fold for EAAT1 and EAAT3, respectively.
The inhibitory potency of the compounds was also confirmed in a native preparation of rat cortical synaptosomes, a model proposed on pharmacological studies to reflect predominantly EAAT2 activity (Dunlop et al., 1999; Tan et al., 1999) . Each of the four compounds exhibited similar inhibitory potencies in the synaptosomal preparation and an identical rank order of potency confirming their property as potent glutamate transport inhibitors and providing further evidence for the identity between EAAT2 mediated uptake and uptake by the transport system expressed in rat cortical synaptosomes.
Additional studies in the synaptosomal preparation were undertaken to determine that the compounds behaved in a manner consistent with competitive inhibitors suggesting that they overlap with the glutamate recognition site on the transporter. Given that the compounds retain the carboxylic acid moiety it is perhaps not surprising that they would exhibit significant overlap with the glutamate-binding site.
A third index used to estimate the inhibitory activity of the most potent and selective compound WAY-213613 was to evaluate its effect on glutamate-induced currents in oocytes expressing each of the transporters. It was observed that the inhibitory potencies for blocking glutamate-induced currents in both EAAT2 and EAAT3 injected oocytes were identical to those determined in the cell line uptake studies, while a 10-fold weaker and 36 nM, respectively). However, while these compounds exhibited 22-and 39-fold selectivity over EAAT3 their inhibitory potencies for EAAT1 were essentially the same as those determined for EAAT2. Although WAY-213613 was slightly less potent than either of these agents the compound was more selective over both EAAT1 and EAAT3.
By generating a pharmacophore model of known EAAT inhibitors and the novel agents reported here we have identified a number of features associated with the newly identified compounds distinct from known EAAT inhibitors. These include the absence of a distal acidic group acting as a hydrogen bond acceptor identified in other known EAAT inhibitors and the presence of a hydrophobic center conferring significant lipophilic volume to the novel agents. Although by no means definitive these observations may provide insight into structural features for selective EAAT2 binding
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